ClinicalTrials.gg
TerminatedNCT03448653Updated Nov 29, 2024Results posted

Contribution of Narrow Band Imaging (NBI) for the Characterization of Scalloped Polyps (NBI POLYPES COLIQUES)

An interventional study of Colonoscopy with NBI in Polyps of Colon, sponsored by Centre Hospitalier Departemental Vendee. Terminated at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Centre Hospitalier Departemental Vendee · Not applicable, Interventional, and Diagnostic

Why this study was terminated
Slow recruitment, advances in technology
Phase
Not applicable
Study type
Interventional
Enrollment
314
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This prospective bicentric trial aims to evaluate the diagnostic performance of the characterization of scalloped polyps less than 20 millimeter in NBI (Narrow Band Imaging) in patients with screening colonoscopy.

The NBI is a so-called "virtual" electronic staining technique available on conventional OLYMPUS endoscopes without additional intervention.

The colonoscopy procedure for each patient will not be different from a conventional colonoscopy examination with excision of all polyps visualized and anatomopathological analysis, except for a short time of analysis in NBI for each polyp detected before excision to classify the polyp in existing endoscopic classifications (ie NICE classification for adenomatous polyps and WASP classification for festooned polyps).

02

Conditions studied

  • Polyps of Colon

Browse trials for

03

In context

Colonic Polyps

326 studies on the registry are indexed under Colonic Polyps; 53 are open to participants now.

This study's enrollment of 314 is above the median of 264 across 221 interventional studies indexed under Colonic Polyps.

Browse Colonic Polyps studies →

Lead sponsor

Centre Hospitalier Departemental Vendee is the lead sponsor of 83 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Pre-inclusion criteria:

  • Major patient with a colonoscopy scheduled in one of the participating hospitals (CHD Vendée and CHU Nantes).
  • Patient who agreed to participate in the study and gave his express consent
  • Patient affiliated with a social security system or beneficiary of a scheme

Inclusion criteria

Inclusion Criteria:

  • Patient with 1 or more polyps less than 20 mm observed during colonoscopy

Exclusion criteria

Exclusion Criteria:

  • Patient with an emergency colonoscopy for ongoing digestive bleeding or occlusion symptoms
  • Patient with chronic inflammatory bowel disease (IBD): Crohn's disease or unclassified colitis
  • Patient with familial adenomatous polyposis
  • Pregnant or lactating woman
  • Minor patient
  • Major patient under tutorship, curatorship, or deprived of liberty
  • Patient unable to understand protocol and / or give express consent
  • Patient not affiliated with a social security system or beneficiary of such a scheme
  • Patient hospitalized or treated without their consent
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Colonoscopy with NBI

    Other: Colonoscopy with NBI

Interventions

  • OtherColonoscopy with NBI

    Colonoscopy with NBI

06

What researchers measure

Primary outcomes

  1. Sensitivity of the NBI Compared to the Anatomopathological Analysis (= Reference Method)

    Number of polyps characterized as scalloped (NICE II-) by NBI relative to the number of polyps characterized as scalloped in standard histology

    Time frame: An average of 1 month

07

Results

Posted Nov 29, 2024

Participant flow

Participant flow — Overall Study
MilestoneColonoscopy With NBI
Started314
Completed314
Not completed0

Outcome measures

PrimarySensitivity of the NBI Compared to the Anatomopathological Analysis (= Reference Method)

Number of polyps characterized as scalloped (NICE II-) by NBI relative to the number of polyps characterized as scalloped in standard histology

Time frame:
An average of 1 month
Reported as:
Number · proportion of positive cases
Sensitivity of the NBI Compared to the Anatomopathological Analysis (= Reference Method)
proportion of positive casesColonoscopy With NBI
Sensitivity of the NBI Compared to the Anatomopathological Analysis (= Reference Method)0.844 (0.803 to 0.879)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Colonoscopy With NBI———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Colonoscopy With NBI
Mean67 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Colonoscopy With NBI
Female117
Male195
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Colonoscopy With NBI
Hispanic or LatinoNA
Not Hispanic or LatinoNA
Unknown or Not Reported312
Region of Enrollment
Region of Enrollment(participants)Colonoscopy With NBI
France312
08

Study locations

2 sites
  • Centre Hospitalier Départemental Vendée
    La Roche-sur-Yon, 85925, France
  • Centre Hospitalier Universitaire Nantes
    Nantes, 44000, France
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 14, 2021

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03448653
Lead sponsor
Centre Hospitalier Departemental Vendee
Responsible party
Sponsor
First posted
Feb 28, 2018
Start date
Jul 9, 2018
Primary completion
Jul 12, 2022
Completion
Jul 12, 2022
Results posted
Nov 29, 2024
Last update
Nov 29, 2024

Study contacts

Vincent MACE
study director · Centre Hospitalier Départemental Vendée

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion